AUSTEDO® XR: Tardive Dyskinesia and Huntingtons Chorea Treatment AUSTEDO® XR (deutetrabenazine) extended-release tablets is the first medication approved to treat both tardive dyskinesia and Huntington's disease chorea See safety info including Boxed Warning
AUSTEDO XR® Medication for Tardive Dyskinesia (TD) Once-daily AUSTEDO XR contains the same active ingredient as twice-daily AUSTEDO® (deutetrabenazine) tablets Data on this page is based on twice-daily dosing
AUS-47312 XR HD:TD AUSTEDO Prescribing Information Digitial v6 AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease Anyone considering the use of AUSTEDO XR or AUSTEDO must balance the risks of depression and suicidality with the clinical need for treatment of chorea
AUS-47311 AUSTEDO and AUSTEDO XR Medication Guide Digital v3 If your healthcare provider plans to switch you from tetrabenazine to AUSTEDO XR or AUSTEDO, take your first dose of AUSTEDO XR or AUSTEDO on the day after your last dose of tetrabenazine
Patient Support Program | AUSTEDO XR® (deutetrabenazine) AUSTEDO XR and AUSTEDO increases your chance of having certain changes in the electrical activity in your heart These changes can lead to a dangerous abnormal heartbeat